Antiviral drug discovery: broad-spectrum drugs from nature (Q38260235)

1 September 2017

1 reference

title

Antiviral drug discovery: broad-spectrum drugs from nature (English)

1 reference

1 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Mark Brönstrup

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Andreas Meyerhans

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

F Sasse

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

J Diez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

1 January 2015

1 reference

1 September 2017

Natural Product Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

29-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

Kinetics of influenza A virus infection in humans

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Global trends in emerging infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Risk factors for human disease emergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The global distribution and burden of dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

SARS--beginning to understand a new virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

MERS: emergence of a novel human coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Emergence of Zaire Ebola Virus Disease in Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Preventing and controlling influenza with available interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Towards hepatitis C eradication from the HIV-infected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

HIV-HBV coinfection--a global challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Integration of antiretroviral therapy with tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The Confirmation and Maintenance of Smallpox Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Airborne transmission of influenza A/H5N1 virus between ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Containing the accidental laboratory escape of potential pandemic influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Gain-of-function research: unknown risks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Novel therapies for hepatitis C - one pill fits all?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Therapy for hepatitis C--the costs of success

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The importance of drug-drug interactions in the DAA era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Drug-drug interactions during antiviral therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Review of drug interactions with telaprevir and antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Transporter-mediated drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral resistance and the future landscape of hepatitis C virus infection therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Identification of transferrin receptor 1 as a hepatitis C virus entry factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Viroporins: structure and biological functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Decrease of virus receptors during highly pathogenic H5N1 virus infection in humans and other mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

CD8 down-regulation and functional impairment of SIV-specific cytotoxic T lymphocytes in lymphoid and mucosal tissues during SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The ESCRT machinery: new functions in viral and cellular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

A pathogenic picornavirus acquires an envelope by hijacking cellular membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

No strings attached: the ESCRT machinery in viral budding and cytokinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Old world arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Genome-wide RNAi screen reveals a role for the ESCRT complex in rotavirus cell entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Virus budding and the ESCRT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Virus-host interactomes--antiviral drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The host interactome of influenza virus presents new potential targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Discovery of insect and human dengue virus host factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

New horizons for antiviral drug discovery from virus-host protein interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Curing a viral infection by targeting the host: the example of cyclophilin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Strategies in the design of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

21 January 2018

HIV and co-infections

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Exploiting drug repositioning for discovery of a novel HIV combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cell biology: Beneficial lessons from viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The yin and yang of viruses and interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Multifaceted roles for lipids in viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Host-cell lipid rafts: a safe door for micro-organisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Subcellular targeting strategies for drug design and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cellular cholesterol trafficking and compartmentalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Endosome-to-cytosol transport of viral nucleocapsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Dissecting the role of COPI complexes in influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Viral infection controlled by a calcium-dependent lipid-binding module in ALIX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Host proteins involved in HIV infection: new therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Genetic inactivation of COPI coatomer separately inhibits vesicular stomatitis virus entry and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Human host factors required for influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Parallels among positive-strand RNA viruses, reverse-transcribing viruses and double-stranded RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Hijacking components of the cellular secretory pathway for replication of poliovirus RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cytoplasmic viral replication complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Viral reorganization of the secretory pathway generates distinct organelles for RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

GGA and Arf proteins modulate retrovirus assembly and release

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

GBF1, a guanine nucleotide exchange factor for Arf, is crucial for coxsackievirus B3 RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mouse Hepatitis Coronavirus RNA Replication Depends on GBF1-Mediated ARF1 Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclophilin A: a key player for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclosporin A inhibits the replication of diverse coronaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclophilin inhibitors for hepatitis C therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclophilin inhibitors as antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Modulating immunity as a therapy for bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Intrinsic antiviral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

A diverse range of gene products are effectors of the type I interferon antiviral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

TLR pathways and IFN-regulatory factors: to each its own.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Dynamins are forever: MxB inhibits HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The broad-spectrum antiviral functions of IFIT and IFITM proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

RIGorous detection: exposing virus through RNA sensing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Targeting Toll-like receptors: emerging therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The path to a successful vaccine adjuvant--'the long and winding road'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Targeting of Toll-like receptors: a decade of progress in combating infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Natural products to drugs: natural product-derived compounds in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Natural products as sources of new drugs over the last 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Novel chemical space exploration via natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Lessons from natural molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cellular targets of natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Natural product mode of action (MOA) studies: a link between natural and synthetic worlds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Natural products as catalysts for innovation: a pharmaceutical industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Industrial natural product chemistry for drug discovery and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antibiotics in the clinical pipeline in 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The influence of natural products upon drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The structure of showdomycin, a novel carbon-linked nucleoside antibiotic related to uridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mechanisms of action of cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclosporin A inhibits vaccinia virus replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Inhibition of herpes simplex virus production in vitro by Cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Statins inhibit HIV-1 infection by down-regulating Rho activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Treating influenza with statins and other immunomodulatory agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The effects of simvastatin or interferon-α on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Statins reduce dengue virus production via decreased virion assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Protective effect of fluvastatin on influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The inhibition of nucleic acid synthesis by mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Ribavirin Reveals a Lethal Threshold of Allowable Mutation Frequency for Hantaan Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Identification of active antiviral compounds against a New York isolate of West Nile virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mutations that confer resistance to mycophenolic acid and ribavirin on sindbis virus map to the nonstructural protein nsP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Castanospermine inhibits the processing of the oligosaccharide portion of the influenza viral hemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral activity and metabolism of the castanospermine derivative MDL 28,574, in cells infected with herpes simplex virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral effects of an iminosugar derivative on flavivirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral effects of glycosylation and glucose trimming inhibitors on human parainfluenza virus type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Roles of N-linked glycans in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Influenza virus entry and infection require host cell N-linked glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Synthesis and biological activity of naturally occurring α-glucosidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antimicrobial and antiviral activity of hydrolysable tannins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Inhibition of human immunodeficiency viral replication by tannins and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral activity of punicalagin toward human enterovirus 71 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Glycosaminoglycans in infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Filoviruses utilize glycosaminoglycans for their attachment to target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral activity of recombinant cyanovirin-N against HSV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

6-0-butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIVs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Effect of glycosylation and glucose trimming inhibitors on the influenza A virus glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral lead compounds from marine sponges

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Griffithsin has antiviral activity against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Lantibiotics: peptides of diverse structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Labyrinthopeptins: a new class of carbacyclic lantibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Heterologous expression and engineering studies of labyrinthopeptins, class III lantibiotics from Actinomadura namibiensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Myxobacteria: natural pharmaceutical factories

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antibiotics from myxobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Myxobacterial secondary metabolites: bioactivities and modes-of-action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Concerted action of P450 plus helper protein to form the amino-hydroxy-piperidone moiety of the potent protease inhibitor crocapeptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Total synthesis of a noricumazole A library and evaluation of HCV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

A superhighway to virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Viral interactions with the cytoskeleton: a hitchhiker's guide to the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

V-ATPase functions in normal and disease processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Virus entry, assembly, budding, and membrane rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Screening of small molecules affecting mammalian P-body assembly uncovers links with diverse intracellular processes and organelle physiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Marine compounds and their antiviral activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Structures of Triacetyloleandomycin and Mycalamide A Bind to the Large Ribosomal Subunit of Haloarcula marismortui

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

The marine natural product manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Serine/threonine protein phosphatase is required for tobacco mosaic virus-mediated programmed cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Viral serine/threonine protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Monomerization of Viral Entry Inhibitor Griffithsin Elucidates the Relationship between Multivalent Binding to Carbohydrates and anti-HIV Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Griffithsin protects mice from genital herpes by preventing cell-to-cell spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Squalamine: an aminosterol antibiotic from the shark

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Membrane phosphatidylserine regulates surface charge and protein localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Defensins: antimicrobial peptides of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral potential of cathelicidins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral mechanisms of human defensins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Structural and Functional Analysis of the Pro-Domain of Human Cathelicidin, LL-37

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Evolutionary conflicts between viruses and restriction factors shape immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Arbidol as a broad-spectrum antiviral: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Dragmacidins: New Protein Phosphatase Inhibitors from a Southern Australian Deep-Water Marine Sponge,Spongosoritessp

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Antiviral and antitumor agents from a New Zealand sponge, Mycale sp. 2. Structures and solution conformations of mycalamides A and B

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00085D

Castanospermine, an HIV inhibitor from tissue cultures ofCastanospermum australe

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/PTR.2650090719

10 April 2024

Identifiers

DOI

10.1039/C4NP00085D

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315648%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference